RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study

Rezolute, Inc. (RZLT) announced that the FDA has removed the partial clinical holds on the phase III study evaluating its lead pipeline candidate RZ358 (ersodetug) for the treatment of hypoglycemia caused by congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder. Shares of the company were up 22.1% on Sept. 9 following the announcement of the news. The double-blind, placebo-controlled phase III sunRIZE study is designed to evaluate the safety and efficacy of RZ358 in patients with congeni ...